Balance Sheet Data

Halozyme Therapeutics, Inc. (HALO)

$41.11

+1.30 (+3.27%)

Year
A/P
2019
Actual
2020
Actual
2021
Actual
2022
Actual
2023
Actual
2024
Projected
2025
Projected
2026
Projected
2027
Projected
2028
Projected
Total Cash 421.26368.01740.92362.793361,470.812,120.643,057.574,408.466,356.19
Total Cash (%)
Account Receivables 59.4497.7390.98231.07234.21360.17519.30748.741,079.551,556.51
Account Receivables (%)
Inventories 29.3660.7553.91100.12127.60192.25277.19399.65576.23830.81
Inventories (%)
Accounts Payable 6.431.931.5417.6911.8220.2229.1542.0460.6187.38
Accounts Payable (%)
Capital Expenditure -4.04-2.50-1.46-4.81-15.29-14.11-20.34-29.32-42.28-60.96
Capital Expenditure (%)



To support growth, companies need to keep investing in capital items – including property, plants and equipment.
To calculate this net investment,we take capital expenditure (found in the company’s statement of cash flows) and subtract non-cash depreciation (found on the income statement).
Working capital refers to the cash a company needs for day-to-day operations.
The faster a company expands, the more cash it will need.
To calculate working capital, we take current assets and subtract current liabilities.
You can find both of these on a company’s balance sheet, which is published in its quarterly and annual financial statements.